237 related articles for article (PubMed ID: 12148903)
1. Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia.
Ozpolat B; Lopez-Berestein G
Leuk Lymphoma; 2002 May; 43(5):933-41. PubMed ID: 12148903
[TBL] [Abstract][Full Text] [Related]
2. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.
Westervelt P; Pollock JL; Oldfather KM; Walter MJ; Ma MK; Williams A; DiPersio JF; Ley TJ
Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9468-73. PubMed ID: 12077315
[TBL] [Abstract][Full Text] [Related]
3. The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
Jing Y; Waxman S
Curr Top Microbiol Immunol; 2007; 313():245-69. PubMed ID: 17217047
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
[TBL] [Abstract][Full Text] [Related]
5. ATRA(ouble) in the treatment of acute promyelocytic leukemia.
Ozpolat B; Lopez-Berestein G; Mehta K
J Biol Regul Homeost Agents; 2001; 15(2):107-22. PubMed ID: 11501968
[TBL] [Abstract][Full Text] [Related]
6. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
7. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
Calleja EM; Warrell RP
Curr Oncol Rep; 2000 Nov; 2(6):519-23. PubMed ID: 11122887
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
9. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid.
Douer D; Estey E; Santillana S; Bennett JM; Lopez-Bernstein G; Boehm K; Williams T
Blood; 2001 Jan; 97(1):73-80. PubMed ID: 11133744
[TBL] [Abstract][Full Text] [Related]
10. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
Tsimberidou AM; Tirado-Gomez M; Andreeff M; O'Brien S; Kantarjian H; Keating M; Lopez-Berestein G; Estey E
Leuk Lymphoma; 2006 Jun; 47(6):1062-8. PubMed ID: 16840198
[TBL] [Abstract][Full Text] [Related]
11. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
12. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
13. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Estey EH; Giles FJ; Kantarjian H; O'Brien S; Cortes J; Freireich EJ; Lopez-Berestein G; Keating M
Blood; 1999 Oct; 94(7):2230-5. PubMed ID: 10498593
[TBL] [Abstract][Full Text] [Related]
14. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Tsimberidou AM; Estey E; Whitman GJ; Dryden MJ; Ratnam S; Pierce S; Faderl S; Giles F; Kantarjian HM; Garcia-Manero G
Leuk Res; 2004 Sep; 28(9):991-4. PubMed ID: 15234578
[TBL] [Abstract][Full Text] [Related]
15. Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid.
Estey E; Koller C; Cortes J; Reed P; Freireich E; Giles F; Kantarjian H
Leuk Lymphoma; 2001 Jul; 42(3):309-16. PubMed ID: 11699395
[TBL] [Abstract][Full Text] [Related]
16. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
17. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
[TBL] [Abstract][Full Text] [Related]
18. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
19. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
Ma Y; Liu L; Jin J; Lou Y
PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027
[TBL] [Abstract][Full Text] [Related]
20. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
